EP4735031A2 - Codonoptimierte pmcmv-sequenzen - Google Patents

Codonoptimierte pmcmv-sequenzen

Info

Publication number
EP4735031A2
EP4735031A2 EP24832850.2A EP24832850A EP4735031A2 EP 4735031 A2 EP4735031 A2 EP 4735031A2 EP 24832850 A EP24832850 A EP 24832850A EP 4735031 A2 EP4735031 A2 EP 4735031A2
Authority
EP
European Patent Office
Prior art keywords
seq
nucleic acid
codon optimized
sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24832850.2A
Other languages
English (en)
French (fr)
Inventor
Jared PATCH
Shrinivasrao P. MANE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of EP4735031A2 publication Critical patent/EP4735031A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP24832850.2A 2023-06-27 2024-06-26 Codonoptimierte pmcmv-sequenzen Pending EP4735031A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363523476P 2023-06-27 2023-06-27
PCT/US2024/035572 WO2025006573A2 (en) 2023-06-27 2024-06-26 Codon optimized pmcv sequences

Publications (1)

Publication Number Publication Date
EP4735031A2 true EP4735031A2 (de) 2026-05-06

Family

ID=93940162

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24832850.2A Pending EP4735031A2 (de) 2023-06-27 2024-06-26 Codonoptimierte pmcmv-sequenzen

Country Status (4)

Country Link
EP (1) EP4735031A2 (de)
DK (1) DK202570141A1 (de)
NO (1) NO20251666A1 (de)
WO (1) WO2025006573A2 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615663B1 (de) * 2003-10-24 2007-12-26 Mologen AG Mittel zur behandlung von infektionen mit leishmanien
EP2560985B1 (de) * 2010-04-21 2016-06-29 Pharmaq AS Nukleinsäuresequenzen eines fischvirus und ihre verwendung

Also Published As

Publication number Publication date
WO2025006573A2 (en) 2025-01-02
WO2025006573A3 (en) 2025-03-06
DK202570141A1 (en) 2026-01-07
NO20251666A1 (en) 2025-12-22

Similar Documents

Publication Publication Date Title
Fodor et al. Induction of protective immunity in chickens immunised with plasmid DNA encoding infectious bursal disease virus antigens
US10308927B2 (en) Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease
Li et al. Enhancement of the immunogenicity of DNA vaccine against infectious bursal disease virus by co-delivery with plasmid encoding chicken interleukin 2
US20250127873A1 (en) Compositions and methods for prevention of piscine myocarditis
WO2014174078A1 (en) Bacterial artificial chromosomes
WO2019023920A1 (zh) 一种口蹄疫病毒样颗粒疫苗及其制备方法
US20250057946A1 (en) Use of interferon as an adjuvant in vaccines
RU2018130683A (ru) Аттенуированный вирус инфекционного бронхита
EP2992005B1 (de) Mutantes spikeprotein zur extension des gewebetropismus des infektiösen bronchitisvirus (ibv)
CN111040024A (zh) 4型禽腺病毒基因工程疫苗及其制备方法与应用
CN111548394A (zh) 禽法氏囊病毒基因工程疫苗及其制备方法与应用
CN120202019A (zh) 重组lsdv载体口蹄疫抗原构建体
WO2025006573A2 (en) Codon optimized pmcv sequences
DK202470171A1 (en) Compositions and methods for expressing antigens on cell membrane
US20070207167A1 (en) Immunologically enhanced recombinant vaccines
Kwon et al. Sequence analysis of the variable VP2 gene of infectious bursal disease viruses passaged in Vero cells
CN1630662A (zh) 兔出血性疾病疫苗及抗原
RU2842174C2 (ru) Композиции и способы профилактики миокардита рыб
RU2854997C2 (ru) Использование интерферона в качестве адьюванта в вакцинах
CN120775802B (zh) 一种鲤疱疹病毒3型orf136基因失活株及其制备方法和应用
EP1170302B1 (de) Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursal-Krankheit
JP2025091235A (ja) バキュロウイルス発現系を用いて豚熱ウイルスのｅ２サブユニットを発現するためのコンストラクト、およびその利用
Duong et al. Expression and purification capsid proteins Vp0, Vp1 and Vp3 of foot and mouth disease virus type O in Escherichia coli
Chansuwan et al. Production of scale drop disease virus self-assembled major capsid protein nanoparticles for fish vaccine development
CN120775801A (zh) 一种鲤疱疹病毒3型orf138基因失活株及其制备方法和应用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR